PET/MRI Imaging with 89Zr-Trastuzumab for Predicting Targeted Therapy Effectiveness in Patients with HER2 Positive Breast Cancer
This phase I trial studies how well PET/MRI with imaging agent 89Zr-trastuzumab works for predicting target therapy effectiveness in patients with HER2 positive breast cancer. PET imaging is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 89Zr-trastuzumab. MRI imaging uses radiofrequency waves and a strong magnetic field rather than x-rays to provide clear and detailed pictures of internal organs and tissues. 89Zr-trastuzumab works by binding to HER2 proteins on the cells, making it easier to take images of the tumor cells. Giving 89Zr-trastuzumab with PET/MRI may enhance imaging quality and may potentially spare patients from having to have multiple biopsies in the future.